WuXi Biologics (Cayman) Inc. (HKG:2269)
Hong Kong
· Delayed Price · Currency is HKD 24.85
-0.85 (-3.31%)
Jun 18, 2025, 4:08 PM HKT
WuXi Biologics Revenue
In the year 2024, WuXi Biologics had annual revenue of 18.68B CNY with 9.63% growth. WuXi Biologics had revenue of 10.10B in the half year ending December 31, 2024, with 25.29% growth.
Revenue
18.68B CNY
Revenue Growth
+9.63%
P/S Ratio
5.09
Revenue / Employee
1.49M CNY
Employees
12,575
Market Cap
101.11B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 18.68B | 1.64B | 9.63% |
| Dec 31, 2023 | 17.03B | 1.77B | 11.56% |
| Dec 31, 2022 | 15.27B | 4.98B | 48.38% |
| Dec 31, 2021 | 10.29B | 4.68B | 83.35% |
| Dec 31, 2020 | 5.61B | 1.63B | 40.88% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines | 32.49B |
| Hansoh Pharmaceutical Group Company | 13.05B |
| Innovent Biologics | 10.03B |
| JD Health International | 61.89B |
| CSPC Pharmaceutical Group | 28.99B |
| Sino Biopharmaceutical | 30.72B |
| Akeso | 2.26B |
| Sichuan Kelun-Biotech Biopharmaceutical | 2.06B |
WuXi Biologics News
- 14 hours ago - Focus: China pharma projects disrupted by Sino-US tensions - Reuters
- 2 days ago - Hong Kong stocks waver on China’s mixed economic data - South China Morning Post
- 9 days ago - WuXi Biologics Kicks off Construction of Microbial Manufacturing Site for Commercial Production in Chengdu - PRNewsWire
- 20 days ago - Hong Kong stocks jump as US blocks Trump’s tariffs in win for global trade - South China Morning Post
- 4 weeks ago - WuXi Biologics: Eyes On Long-Term Risks And Near-Term Outlook (Rating Downgrade) - Seeking Alpha
- 4 weeks ago - WuXi Biologics Congratulates Partner CANbridge Pharmaceuticals on the Approval of Innovative Velaglucerase-beta for Injection (Gaurunning) for Gaucher Disease by China NMPA - PRNewsWire
- 7 weeks ago - Driving Impact Through Responsibility: WuXi Biologics Releases 2024 Sustainability Report - PRNewsWire
- 2 months ago - WuXi Biologics Recognized by CDP for Climate Change Leadership for Second Consecutive Year - PRNewsWire